Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting (CINV)
Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Trial Timeline
Apr 1, 2010 → Oct 1, 2010
NCT ID
NCT01111851About Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999
Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999 is a phase 1 stage product being developed by Merck for Chemotherapy-Induced Nausea and Vomiting (CINV). The current trial status is completed. This product is registered under clinical trial identifier NCT01111851. Target conditions include Chemotherapy-Induced Nausea and Vomiting (CINV).
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Nausea and Vomiting (CINV) were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01111851 | Phase 1 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting (CINV)